Meet the Volume Editors

Xianquan Zhan received his MD and Ph.D. in Preventive Medicine at West China University of Medical Sciences. He received his post-doctoral training in oncology and cancer proteomics at Central South University, China, and University of Tennessee Health Science Center (UTHSC), USA. He worked at UTHSC and the Cleveland Clinic in 2001–2012 and achieved the rank of associate professor at UTHSC. Currently, he is a full professor

at Central South University and Shandong First Medical University, both in China, and an advisor to MS/PhD students and postdoctoral fellows. He is also a fellow of the Royal Society of Medicine and European Association for Predictive Preventive Personalized Medicine (EPMA), a national representative of EPMA, and a member of the American Society of Clinical Oncology (ASCO) and the American Association for the Advancement of Sciences (AAAS). He is also editor in chief of the *International Journal of Chronic Diseases & Therapy*, an associate editor of *EPMA Journal, Frontiers in Endocrinology*, and *BMC Medical Genomics*, and a guest editor of *Mass Spectrometry Reviews, Frontiers in Endocrinology, EPMA Journal*, and *Oxidative Medicine and Cellular Longevity*. He has published more than 170 articles, 29 book chapters, 8 books, and 3 international patents in the field of clinical proteomics and biomarkers.

Dr. Atena Jabbari received her BS in Chemistry in 2006, MS and Ph.D. in Organic Chemistry in 2010 and 2016, respectively, from Ferdowsi University of Mashhad, Iran. She conducted postdoctoral research at the Department of Medicinal Chemistry, School of Pharmacy, Mashhad University of Medical Sciences, Iran, in 2018. Dr. Jabbari is currently an Assistant Project Scientist at the Department of Chemistry and Biochemistry, University of California, Los

Angeles (UCLA), USA. Her research interests include the synthesis of complex small molecules with biological activity, total synthesis of natural products, enzyme inhibition, and targeted cancer therapy. Her research studies have focused on drug design, synthesis of complex small molecules as enzyme inhibitors, SAR (Structure-Activity Relationship) studies, and targeted cancer treatment. She serves as an editorial board member and reviewer for several journals.

## Contents

